Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Dec 17, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding more about a genetic condition called Autosomal Dominant Polycystic Kidney Disease (ADPKD), specifically looking at the PKD1 and PKD2 gene variants that can affect it. Researchers want to see how common these gene variants are and how they influence the health and characteristics of people living with ADPKD. By gathering this information, they hope to improve our understanding of the disease and how it affects different individuals.

To be eligible for the study, you must have a diagnosis of ADPKD and a certain level of kidney function (measured by something called eGFR) that shows your kidneys are still working to some extent. Participants should be willing to attend scheduled visits and follow study procedures. If you have other serious kidney diseases, have had a kidney transplant, or are on certain treatments, you may not be able to join. Those who participate can expect regular check-ups and to contribute to important research that could help others with ADPKD in the future.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 30 milliliter per minute (mL/min)/1.73 m\^2
• • Willing and able to comply with scheduled visits and other study procedures
• • A pre-existing diagnosis of ADPKD as defined in the protocol
• Key Exclusion Criteria:
• • History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD
• • History of solid organ or bone marrow transplantation or nephrectomy
• • Ongoing renal replacement therapy or planning to start renal replacement therapy less than or equal to (≤)12 months from the Genotyping Visit in Part A
• • Other protocol defined Inclusion/Exclusion criteria will apply.